PMID- 22271340
OWN - NLM
STAT- MEDLINE
DCOM- 20120727
LR  - 20220318
IS  - 1520-6017 (Electronic)
IS  - 0022-3549 (Linking)
VI  - 101
IP  - 5
DP  - 2012 May
TI  - Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus.
PG  - 1647-58
LID - 10.1002/jps.23057 [doi]
AB  - Various complex mechanisms and their multifactorial pathways decisively provoke 
      low-grade local and systemic inflammation in beta-cells of pancreatic islets and 
      peripheral tissues to induce beta-cells' dysfunction and apoptosis, insulin 
      resistance, and ultimately, overt type 2 diabetes mellitus (T2DM). Conventional 
      antidiabetic agents are being less popular, as they have some potential adverse 
      effects. Currently, many anti-inflammatory therapeutic modalities are being 
      investigated to abate the infuriating effects of inducers of T2DM and among them, 
      interleukin-1 receptor antagonist (IL-1Ra) is the only one that has been approved 
      by US Food and Drug Administration. We have compared IL-1Ra with other 
      anti-inflammatory agents and conventional antidiabetic agents. Although, IL-1Ra 
      has broad-spectrum anti-inflammatory activities, it also has some limitations due 
      to its short half-life. To overcome the problem of short half-life of IL-1Ra, 
      recently, we fused IL-1Ra in recombinant human serum albumin and expressed it in 
      Pichia pastoris. Its bioactivity was also checked by IL-1-induced A375.S2 
      apoptotic cells. Furthermore, we have also formulated IL-1Ra with Pluronic 
      F-127-based thermosensitive gel and investigated its in vitro characteristics to 
      prolong its therapeutic effects. Further studies are required to investigate its 
      therapeutic effects against diabetes and diabetes-associated complications.
CI  - Copyright (c) 2012 Wiley Periodicals, Inc.
FAU - Akash, Muhammad Sajid Hamid
AU  - Akash MS
AD  - Institute of Pharmacology, Toxicology and Biochemical Pharmaceutics, College of 
      Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang Province 310058, 
      China.
FAU - Shen, Qi
AU  - Shen Q
FAU - Rehman, Kanwal
AU  - Rehman K
FAU - Chen, Shuqing
AU  - Chen S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120123
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin 1 Receptor Antagonist Protein)
SB  - IM
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Drug Approval
MH  - Half-Life
MH  - Humans
MH  - Inflammation Mediators/physiology
MH  - Interleukin 1 Receptor Antagonist Protein/pharmacokinetics/*therapeutic use
MH  - Oxidative Stress
MH  - United States
MH  - United States Food and Drug Administration
EDAT- 2012/01/25 06:00
MHDA- 2012/07/28 06:00
CRDT- 2012/01/25 06:00
PHST- 2011/01/04 00:00 [accepted]
PHST- 2011/11/26 00:00 [received]
PHST- 2011/12/27 00:00 [revised]
PHST- 2012/01/25 06:00 [entrez]
PHST- 2012/01/25 06:00 [pubmed]
PHST- 2012/07/28 06:00 [medline]
AID - S0022-3549(15)31599-9 [pii]
AID - 10.1002/jps.23057 [doi]
PST - ppublish
SO  - J Pharm Sci. 2012 May;101(5):1647-58. doi: 10.1002/jps.23057. Epub 2012 Jan 23.